Personalized DAPT Benefit Risk Decision Tool

Clinical calculation support · Verify results before clinical use

Clinical risk assessment

Select the clinician-assessed risk categories and whether long-term oral anticoagulation is indicated.

Decision support · ACS

Use a structured assessment where appropriate. These labels are not a substitute for ARC-HBR criteria or a validated bleeding-risk score.

Consider clinical history, coronary anatomy, procedural complexity, and prior ischemic events.

Select “Yes” only when there is an established indication for ongoing oral anticoagulation.

Reset

Clinical context

This tool supports a structured discussion of antithrombotic therapy after acute coronary syndrome (ACS). It does not calculate an individualized net clinical benefit, and the category labels are clinician-entered descriptors rather than validated scores.

For ACS patients who are not at high bleeding risk, the 2025 ACC/AHA ACS guideline recommends aspirin plus an oral P2Y12 inhibitor for at least 12 months as the default. Selected patients may use bleeding-reduction strategies, including ticagrelor monotherapy after at least 1 month of tolerated DAPT, or single antiplatelet therapy after 1 month in selected high-bleeding-risk patients.

Practical checks before choosing a strategy

  • Confirm the ACS presentation, management strategy, date of PCI, and current antithrombotic regimen.
  • Assess bleeding risk with a structured method where appropriate, and do not equate a subjective “high” label automatically with ARC-HBR.
  • Review stent and procedural complexity, prior MI or stent thrombosis, recurrent ischemia, anemia, renal function, frailty, tolerance, and adherence.
  • If long-term oral anticoagulation is indicated, explicitly document the planned duration of triple therapy and when aspirin should be stopped.
  • Consider a proton pump inhibitor when gastrointestinal bleeding risk is elevated and antithrombotic therapy is required.

References

2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes.

J Am Coll Cardiol. DOI: 10.1016/j.jacc.2024.11.009

Urban P, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk.

Eur Heart J. 2019;40:2632–2653. DOI: 10.1093/eurheartj/ehz372

Byrne RA, et al. 2023 ESC Guidelines for the management of acute coronary syndromes.

Eur Heart J. 2023;44:3720–3826. DOI: 10.1093/eurheartj/ehad191

Clinical disclaimer: This decision-support tool is not a validated risk score and must not be used as the sole basis for prescribing, stopping, or extending antithrombotic therapy. Confirm current guideline recommendations, contraindications, patient-specific bleeding and ischemic factors, and local protocols. Decisions should be made by the treating clinician with the patient when appropriate.